Taysha Gene Therapies, Inc.

Research and development expenses were $38.6 million for the 3 months ended June 30, 2026, up from $20.1 million a year earlier. General and administrative expenses were $12.1 million versus $8.6 million last year. Net loss was $46.6 million, or $0.13 per share, compared with a net loss of $26.9 million, or $0.09 per share, in the prior-year quarter. Cash and cash equivalents were $455.4 million as of June 30, 2026, reflecting gross proceeds of $230 million from the June 2026 follow-on financing. Management said current cash resources should support planned operating expenses and capital requirements into the second half of 2028. No full-year revenue or EPS guidance was given.

Sean Nolan framed the quarter as a period of strong execution across clinical, manufacturing, payer, and launch-readiness work. He emphasized that the company is moving toward a potential BLA for TSHA-102 with a plan that could use the 6-month interim analysis as the basis for filing, and said the company believes it may accelerate the submission timeline by at least two full quarters versus waiting for 12-month data. His tone was confident and upbeat, repeatedly describing TSHA-102 as potentially transformative and highlighting strength in the data, manufacturing setup, and balance sheet.

Kamran Alam focused on the higher spend tied to development and launch preparation. R&D rose to $38.6 million from $20.1 million, mainly because of BLA-enabling PPQ manufacturing initiatives, higher clinical trial activity in REVEAL and ASPIRE, and added R&D headcount; G&A increased to $12.1 million from $8.6 million due to compensation and commercial launch-readiness costs. He reported $455.4 million in cash and cash equivalents at quarter-end, including the $230 million gross proceeds from the June 2026 financing, and said this runway should carry the company into the second half of 2028.

Analysts pressed on the Grade 2 neuropathy case, asking whether it reflects AAV-related risk, whether the FDA has commented, and whether monitoring or outpatient administration would change; management said the event was disclosed to the FDA and IDMC, and neither raised concerns or asked for changes. Questions also focused on payer research, seizure data, over-enrollment, and the commercialization plan. Management said payers cared most about durable functional gains, safety, and the outpatient convenience of intrathecal dosing, while CMC/comparability work was described as in good shape and not on the critical path beyond completing PPQ runs and FDA discussion.